Category: Exclusive
-
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies WASHINGTON — President Trump often brags that the “most-favored nation” deals he struck with drugmakers have set the country on a new path to no longer paying more than its fair share for prescription drug costs. But many details of the…
-
STAT+: Cigna, extending reach into prescription drugs, acquires major pharmacy used by hospitals
STAT+: Cigna, extending reach into prescription drugs, acquires major pharmacy used by hospitals Cigna has acquired CarepathRx, a large pharmacy backed by private equity that dispenses prescription drugs to nearly 10% of U.S. hospitals. The acquisition, discovered by STAT in a review of Cigna’s financial filings, reinforces the company’s push to control more of the…
-
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA
STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA An experimental therapy for a rare blood cancer was on the path toward approval by the Food and Drug Administration last year — with internal reviewers recommending it be cleared — before the agency rejected the drug last…
-
STAT+: In first speech to her FDA staff, Høeg says she’ll scrutinize RSV shots and SSRIs in pregnancy
STAT+: In first speech to her FDA staff, Høeg says she’ll scrutinize RSV shots and SSRIs in pregnancy WASHINGTON — Tracy Beth Høeg, the top drug regulator at the Food and Drug Administration, indicated in her first address to staff that she’ll scrutinize antidepressants and the shots used to protect babies from RSV. Høeg told…
-
STAT+: The federal directory of doctors and hospitals is coming this year
STAT+: The federal directory of doctors and hospitals is coming this year After years of grand ambitions, the federal government disclosed that it is months away from rolling out a centralized list of doctors and hospitals filled with up-to-date contact and insurance information. Details of how the national provider directory will work are scant —…
-
STAT+: Epic launches AI Charting, potentially scrambling the ambient scribe market
STAT+: Epic launches AI Charting, potentially scrambling the ambient scribe market The nation’s largest electronic health record company, Epic Systems, announced on Wednesday more details around its long-anticipated AI Charting feature, which could disrupt the market for ambient scribes. Several health systems are piloting the tools now, the company said. “I almost bristle a little…
-
STAT+: FDA Commissioner Marty Makary tries to soothe staff concerns over voucher program
STAT+: FDA Commissioner Marty Makary tries to soothe staff concerns over voucher program WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff and external concerns about a controversial new program to fast-track certain drugs. “This pilot is an effort to make our review processes patient-centric,” said…
-
STAT+: AI biotech founded by ex-Google CEO Eric Schmidt is raising $150 million
STAT+: AI biotech founded by ex-Google CEO Eric Schmidt is raising $150 million Hologen, a secretive AI startup co-founded by former Google CEO Eric Schmidt, is seeking to raise $150 million in a Series A fundraising round, STAT has learned. Hologen describes itself as a “frontier medical AI company, a drug development & diagnostics company,…
-
STAT+: Behind new dietary guidelines: Industry-funded studies, opaque science, crushing deadline pressure
STAT+: Behind new dietary guidelines: Industry-funded studies, opaque science, crushing deadline pressure WASHINGTON — In early May, Health and Human Services Secretary Robert F. Kennedy Jr. had good news for the President: updated dietary guidelines, which were due at the end of 2025, would be delivered ahead of schedule. “We are working very, very fast…
-
STAT+: Panel behind new dietary guidelines had financial ties to beef, dairy industries
STAT+: Panel behind new dietary guidelines had financial ties to beef, dairy industries A group of researchers that formed the scientific basis of new dietary guidelines included people with financial ties to the beef and dairy industries, as well as food companies and other groups. Meat and dairy products received prime placement in new dietary…
-
STAT+: Director of NIH neurological disorders institute is ousted, adding to leadership churn
STAT+: Director of NIH neurological disorders institute is ousted, adding to leadership churn Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke, will soon be leaving his role, STAT has learned. His departure in the coming days means nearly half the 27 NIH divisions will have interim leaders. Koroshetz sent an email…
-
STAT+: Kennedy vaccine adviser to take a new role at CDC on children’s health research
STAT+: Kennedy vaccine adviser to take a new role at CDC on children’s health research WASHINGTON — A vaccine adviser at the Centers for Disease Control and Prevention with ties to health secretary Robert F. Kennedy Jr. is being given a new portfolio that will have him overseeing research into adverse childhood experiences, according to…
-
STAT+: NIH specifies how grant reviewers should ensure alignment with Trump priorities
STAT+: NIH specifies how grant reviewers should ensure alignment with Trump priorities Signaling a move toward the next phase of change, leaders at the National Institutes of Health have sent new guidance to its staff on how to further move its $39 billion portfolio in alignment with the Trump administration’s priorities. The seven-page guidance, sent…
-
STAT+: Acting head of beleaguered mental health agency to depart this week
STAT+: Acting head of beleaguered mental health agency to depart this week Art Kleinschmidt, the official serving as the de facto head of the federal agency overseeing mental health and addiction treatment, is leaving his post on Friday, according to an email reviewed by STAT. Kleinschmidt has led the Substance Abuse and Mental Health Services…
-
STAT+: Hengrui, BeOne top new analysis of Chinese drug development
STAT+: Hengrui, BeOne top new analysis of Chinese drug development A new report is peeling back the curtain on Chinese pharmaceutical innovation, assessing which companies are best at driving the drug development that’s captured the attention of pharmaceutical executives and investors worldwide. On Sunday, IDEA Pharma and parent company SAI MedPartners released their inaugural China…
-
STAT+: FDA removes longtime over-the-counter drugs regulator from her position
STAT+: FDA removes longtime over-the-counter drugs regulator from her position WASHINGTON — The Food and Drug Administration removed the longtime director of the office of over-the-counter drugs from her position on Wednesday, six agency sources told STAT. Theresa Michele, director of the Office of Nonprescription Drugs, has worked at the FDA since at least 2015.…
-
STAT+: Top drug regulator Richard Pazdur set to leave the FDA
STAT+: Top drug regulator Richard Pazdur set to leave the FDA WASHINGTON — Top drug regulator Richard Pazdur has filed papers to retire from the Food and Drug Administration at the end of this month, adding to the turmoil atop the agency. Pazdur informed leaders at the FDA’s drug center of his intention to leave…
-
STAT+: Major health insurers like Humana, UnitedHealth are cutting broker commissions to avoid costly Medicare enrollees
STAT+: Major health insurers like Humana, UnitedHealth are cutting broker commissions to avoid costly Medicare enrollees Major health insurers are taking drastic steps to discourage older adults from signing up for their private Medicare plans as they seek to boost profits, drawing the ire of insurance brokers and state regulators. Humana, UnitedHealthcare, Anthem, and Centene,…
-
STAT+: CDC moves to end telework for employees, including those with medical needs
STAT+: CDC moves to end telework for employees, including those with medical needs The Centers for Disease Control and Prevention has ended full-time telework agreements for reasonable accommodations for many employees, according to multiple employees familiar with the policy. Supervisors in some centers have been told in recent days that they can no longer approve…
-
STAT+: FDA review staff was excluded from voting on whether to approve first priority voucher drug
STAT+: FDA review staff was excluded from voting on whether to approve first priority voucher drug WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one- to two-month drug review, culminating in a one day “tumor board” style meeting where leaders decide whether to approve the drug. …
-
STAT+: AbbVie cuts ties with Google-backed longevity company, lays off scientists
STAT+: AbbVie cuts ties with Google-backed longevity company, lays off scientists AbbVie is ending a decade-long partnership with Calico Life Sciences, an Alphabet-funded biotech company focused on aging research, and laying off chemists working on discovering new drugs. The moves, detailed in internal emails sent Tuesday and viewed by STAT, come as the pharmaceutical giant…
-
STAT+: FDA broadens search for new top drug regulator after early setbacks
STAT+: FDA broadens search for new top drug regulator after early setbacks WASHINGTON — The Food and Drug Administration is struggling to select a new head of its drug center after the sudden and chaotic exit of the previous director, George Tidmarsh. Richard Pazdur, the director of the FDA’s Oncology Center for Excellence, was approached about…
-
STAT+: Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down
STAT+: Arena BioWorks, an ambitious biomedical institute backed by billionaires, abruptly shuts down Arena BioWorks, the buzzy research institute that launched nearly two years ago with $500 million to support a decade of scientific R&D, is abruptly shutting down, the institute confirmed to STAT. Approximately 50 staff members, including co-founder Stuart Schreiber and CEO Harvey…
-
STAT+: FDA’s top drug regulator placed on leave amid investigation
STAT+: FDA’s top drug regulator placed on leave amid investigation WASHINGTON — George Tidmarsh, the Food and Drug Administration’s top regulator of drugs, has been placed on administrative leave after being accused of using his regulatory authority to inflict financial harm on a former business associate, STAT has learned. FDA Commissioner Marty Makary relieved Tidmarsh of…
-
STAT+: How the first nine drug companies won priority review vouchers from Marty Makary’s FDA
STAT+: How the first nine drug companies won priority review vouchers from Marty Makary’s FDA WASHINGTON — Commissioner Marty Makary wants the Food and Drug Administration to move more quickly. The launch of a new priority review voucher program in June was no exception. The agency promised winners a one- to two-month review of their drug…
-
STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies
STAT+: CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies For the past three months, CVS Caremark has resisted adding a new Gilead Sciences HIV prevention drug to its formularies, repeatedly explaining there are “clinical, financial, and regulatory considerations” that must be reviewed before…
-
STAT+: Deep cuts made to CDC’s flagship MMWR publication, a cornerstone of public health
STAT+: Deep cuts made to CDC’s flagship MMWR publication, a cornerstone of public health WASHINGTON — Centers for Disease Control and Prevention staff behind the agency’s flagship publication have suffered deep cuts as part of the firings the Health and Human Services Department has blamed on the government shutdown, according to five people familiar with the situation. Almost the…
-
STAT+: Top Democrat demands more detail from Medicare insurers about their use of AI
STAT+: Top Democrat demands more detail from Medicare insurers about their use of AI Sen. Richard Blumenthal (D-Conn.) is pressing the nation’s largest Medicare Advantage insurers to provide more detail about their use of artificial intelligence tools amid reports that these companies are rapidly increasing their reliance on the technology to help make decisions about…
-
STAT+: Pharma companies scramble to make deals with Trump after Pfizer scored White House praise
STAT+: Pharma companies scramble to make deals with Trump after Pfizer scored White House praise WASHINGTON — The agreement between Pfizer and the Trump administration to lower drug prices has sent other companies scrambling to make a deal. Several major pharmaceutical firms that received letters from President Trump demanding lower prices have been hustling to…
-
STAT+: UnitedHealth taps Duke scientist to lead AI efforts
STAT+: UnitedHealth taps Duke scientist to lead AI efforts UnitedHealth Group has tapped a Duke University artificial intelligence expert to be its chief AI scientist as the health care giant ramps up the use of the technology across its sprawling network of businesses, according to a memo obtained by STAT. Michael Pencina, chief data scientist…
-
STAT+: Trump administration backs off 100% pharma tariffs threatened to start today
STAT+: Trump administration backs off 100% pharma tariffs threatened to start today WASHINGTON — President Trump told pharmaceutical companies last week that they should start building infrastructure in the U.S. — or face a 100% tariff, starting Wednesday. But a White House official told STAT on Wednesday that the tariffs have not gone into effect…
-
STAT+: Anthony Letai of Dana-Farber is front-runner to lead National Cancer Institute
STAT+: Anthony Letai of Dana-Farber is front-runner to lead National Cancer Institute Anthony Letai, a cancer researcher and oncologist at the Dana-Farber Cancer Institute and Harvard University, has emerged as a leading candidate to be the next director of the National Cancer Institute, according to multiple sources with direct knowledge of the situation. The NCI…
-
STAT+: HHS abruptly cancels CDC meeting with RFK Jr., anti-vaccine activist as scrutiny mounts
STAT+: HHS abruptly cancels CDC meeting with RFK Jr., anti-vaccine activist as scrutiny mounts A meeting of health secretary Robert F. Kennedy Jr., anti-vaccine campaigner David Geier, and leaders of the country’s most robust vaccine safety database was abruptly canceled Wednesday, just hours before they were likely to discuss using the data to investigate whether…
-
STAT+: Hill staff gets briefed on implications of Trump’s drug pricing plan
STAT+: Hill staff gets briefed on implications of Trump’s drug pricing plan WASHINGTON — Congress is again discussing the Trump administration’s plan to force drug companies to lower their U.S. prices, at least behind the scenes. Congressional staffers and health policy experts from major think tanks held a closed-door meeting to discuss policy options that…
-
STAT+: FDA will convene Digital Health Advisory Committee in November
STAT+: FDA will convene Digital Health Advisory Committee in November The Food and Drug Administration will convene a meeting of external digital health advisors on Nov. 6, according to an email reviewed by STAT. The gathering comes as the agency wrestles with myriad issues related to regulating artificial intelligence and other technologies in health care.…
-
STAT+: After ousting CDC’s director, RFK Jr. mirrors her ideas to reform the agency
STAT+: After ousting CDC’s director, RFK Jr. mirrors her ideas to reform the agency WASHINGTON — In the days after health secretary Robert F. Kennedy Jr. pushed out the director of the Centers for Disease Control and Prevention, he suggested sweeping changes were needed to reform the agency — and that the ouster was part…
-
STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds
STAT+: Gilead wants state AIDS drug programs to pay significant price hikes for HIV meds Gilead Sciences, the largest maker of HIV medicines, is seeking to boost prices significantly for several treatments that are widely distributed by state AIDS Drug Assistance Programs. And the move is adding to financial uncertainty for the programs on top…
-
STAT+: Abridge CEO downplays impact of Epic’s new AI on call with customers
STAT+: Abridge CEO downplays impact of Epic’s new AI on call with customers Artificial intelligence company Abridge held a meeting with hospital customers on Thursday to address “confusion” about how it may be impacted by new AI products coming to Epic Systems’ widely used electronic health record software. At its annual customer meeting last week,…
-
CDC attacker likely attempted to enter campus days before shooting
CDC attacker likely attempted to enter campus days before shooting WASHINGTON — The man who attacked the Centers for Disease Control and Prevention probably tried to enter the agency’s Atlanta campus days before the shooting, investigators believe. The shooter, identified by authorities as Patrick Joseph White, appears to have been captured in security camera footage…
-
STAT+: Major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, FDA finds
STAT+: Major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, FDA finds Cat hair, pests, bacteria, and equipment failures. These were among the concerns of a recent regulatory inspection of a key, but historically troubled, manufacturing plant that Novo Nordisk bought last year as part of its parent company’s…
-
STAT+: Drugmakers form new group to lobby on impact of Medicare drug price negotiations
STAT+: Drugmakers form new group to lobby on impact of Medicare drug price negotiations WASHINGTON — A handful of drug companies have formed a group to present lawmakers with research on what the industry sees as the negative impacts of Medicare drug price negotiations, according to lobbying records. The group is called the IRA Watchdog…
-
In internal FDA town hall, employees raise concerns about staffing, impromptu expert meetings
In internal FDA town hall, employees raise concerns about staffing, impromptu expert meetings WASHINGTON — Top drug regulator George Tidmarsh assured Food and Drug Administration staff this week that he and other leaders are trying to bring operations back to normal. “I know that I’m coming in here at a challenging time,” Tidmarsh said at…
-
STAT+: AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills
STAT+: AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills A patient advocacy group is suing the Trump administration for failing to disclose details of a recent settlement with Gilead Sciences over the patent rights to a pair of HIV prevention pills. The deal, which was reached last January, capped…
-
STAT+: Inside the fall of Vinay Prasad at the FDA
STAT+: Inside the fall of Vinay Prasad at the FDA Vinay Prasad had a problem. Several, actually. His staff at the Food and Drug Administration kept leaking to the press. He was under attack by President Trump’s allies after moving to pull a gene therapy off the market. Democrats were not happy with his Covid…
-
STAT+: Top White House pandemic preparedness official resigns, officials say, in sign of broader disarray
STAT+: Top White House pandemic preparedness official resigns, officials say, in sign of broader disarray When reports circulated in February that the White House had selected biosecurity expert Gerald Parker as the head of its Office of Pandemic Preparedness and Response Policy, there was palpable relief among infectious disease experts. As former commander of the…
-
STAT+: Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says
STAT+: Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says Sarepta Therapeutics, the maker of a gene therapy for Duchenne muscular dystrophy that is being temporarily shelved because of safety concerns, faces an “arduous and treacherous path” to try to get it back onto the market, a senior Food and…
-
STAT+: HHS backtracks on pledge to disclose new vaccine advisers’ conflicts of interest
STAT+: HHS backtracks on pledge to disclose new vaccine advisers’ conflicts of interest WASHINGTON — The Department of Health and Human Services is sitting on information about new vaccine advisers’ conflicts of interest, and seemingly backtracking on its vow to make key disclosure documents public. Agency officials previously said they would release ethics forms for…
-
STAT+: HHS devises legal playbook for future grant terminations, internal memo shows
STAT+: HHS devises legal playbook for future grant terminations, internal memo shows As the National Institutes of Health recently paused its campaign to terminate billions of dollars in grants, its parent agency was starting to lay out a more cautious and legally rigorous strategy for canceling research deemed out of step with Trump administration priorities,…
-
STAT+: NIH halts grant terminations ‘effective immediately,’ email says
STAT+: NIH halts grant terminations ‘effective immediately,’ email says Days after a federal judge ordered the restoration of more than 1,000 biomedical research grants, the National Institutes of Health is halting further terminations of grants, an internal email shows. Since President Trump’s inauguration in January, the nation’s largest biomedical research funder has terminated an unprecedented…
-
STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire
STAT+: Top FDA drug regulator tells staff much is still in flux, as she prepares to retire WASHINGTON — Outgoing Food and Drug Administration regulator Jacqueline Corrigan-Curay acknowledged to staff that much is still in flux at the agency, weeks before she retires. “We are leaner and therefore we have to find ways to be…
-
STAT+: Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official
STAT+: Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official The ouster of the Food and Drug Administration’s chief regulator of cell and gene therapies earlier this week came immediately after a disagreement with her boss over the review of a cell therapy for Duchenne muscular dystrophy, STAT has…
-
STAT+: Top gene therapy regulator forced out at FDA
STAT+: Top gene therapy regulator forced out at FDA Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy Rachael Anatol have been placed on administrative leave and escorted out of the agency, according to a recording of a meeting obtained by STAT. Verdun…
-
STAT+: Cassidy is circulating a proposed law to push down U.S. drug prices, backing a key Trump ambition
STAT+: Cassidy is circulating a proposed law to push down U.S. drug prices, backing a key Trump ambition WASHINGTON — Senate health committee Chair Bill Cassidy (La.) is the latest Republican to take an interest in legislation that would tie U.S. brand drug prices to lower prices in other wealthy countries, according to seven people…
-
Exclusive: Coalition for Health AI will help The Joint Commission write responsible AI ‘playbooks’
Exclusive: Coalition for Health AI will help The Joint Commission write responsible AI ‘playbooks’ The Joint Commission is forming a partnership with the Coalition for Health AI to develop responsible AI “playbooks,” tools, and a new certification program for health AI, STAT has learned. The partnership brings together the expertise of the health AI trade…
-
STAT+: With U.S. vaccine policy in flux, four members of CDC advisory panel receive termination notices
STAT+: With U.S. vaccine policy in flux, four members of CDC advisory panel receive termination notices Four members of the 19-person expert panel that advises the Centers for Disease Control and Prevention on vaccination policy have been informed that their status as special government employees has been terminated — a development that throws into question…
-
STAT+: Internal document shows how UnitedHealth executives prepared to tamp down investor unrest
STAT+: Internal document shows how UnitedHealth executives prepared to tamp down investor unrest An internal document drafted in advance of UnitedHealth Group’s shareholder meeting this week reveals how the company’s leadership — facing an extraordinary series of financial and legal challenges — sought to downplay complaints about its business practices and assure jittery investors that…
-
STAT+: Reeling from Trump contract cuts, the National Academies prepares for ‘a fairly radical downsizing’
STAT+: Reeling from Trump contract cuts, the National Academies prepares for ‘a fairly radical downsizing’ The National Academies of Sciences, Engineering, and Medicine is headed for a major reorganization as it tries to reduce its overhead amid big losses in funding from the federal government. Facing a shortfall of roughly $40 million in terminated contracts,…
-
STAT+: UnitedHealth’s Optum working on Medicare risk scoring system that would use AI
STAT+: UnitedHealth’s Optum working on Medicare risk scoring system that would use AI SAN DIEGO — Optum, the health data and care provider division of UnitedHealth Group, is developing a way to calculate how sick Medicare patients are through artificial intelligence, instead of relying solely on diagnosis codes submitted by physicians. Ken Cohen, a physician…
-
STAT+: Overseas grants could be ‘closed down’ by NIH under new policy, internal email suggests
STAT+: Overseas grants could be ‘closed down’ by NIH under new policy, internal email suggests A National Institutes of Health policy change on funding of foreign scientists is far more sweeping than described in a Thursday announcement, according to an internal email that indicates international clinical trials and other research will be strictly vetted going…
-
NIH cancels participation in Safe to Sleep campaign that decreased infant deaths
NIH cancels participation in Safe to Sleep campaign that decreased infant deaths WASHINGTON — The Trump administration has cancelled federal participation in Safe to Sleep, a 30-year campaign to prevent babies from dying in their sleep, STAT and the Medill News Service have learned. The elimination of the National Institutes of Health’s role in the…
-
STAT+: No new autism registry, HHS says, walking back NIH director’s claim
STAT+: No new autism registry, HHS says, walking back NIH director’s claim The federal health department is not creating a new registry of Americans with autism, a Department of Health and Human Services official said in a written statement Thursday. Instead, the official said, HHS will launch a $50 million research effort to understand the…
-
STAT+: New England Journal of Medicine gets swept up in U.S. attorney inquiry into alleged bias
STAT+: New England Journal of Medicine gets swept up in U.S. attorney inquiry into alleged bias Last week, at least one scientific journal received a letter from a top U.S. attorney asking it to respond to alleged bias. Now, one of the world’s leading medical journals, has received a similar inquiry as well. The New…
-
STAT+: Biotech entrepreneur Sam Waksal accused of ‘reckless conduct’ in new lawsuit
STAT+: Biotech entrepreneur Sam Waksal accused of ‘reckless conduct’ in new lawsuit Sam Waksal is once again in legal trouble. The biotech entrepreneur, who was famously convicted of insider trading in 2003, allegedly breached his fiduciary duties and engaged in “grossly negligent and reckless conduct” as the chairman, CEO, and largest shareholder of Equilibre Biopharmaceuticals,…
-
STAT+: NIH bans all future grants to universities with DEI programs or Israel boycotts
STAT+: NIH bans all future grants to universities with DEI programs or Israel boycotts The National Institutes of Health will begin prohibiting the awarding of new grants to any institutions that have DEI programs or boycott Israeli companies, in an escalation of the Trump administration’s use of research funding as leverage to dismantle activities at…
-
STAT+: Key NIH grant review panels resume meeting, but are not ‘back to normal’
STAT+: Key NIH grant review panels resume meeting, but are not ‘back to normal’ After being indefinitely suspended in the first days of the Trump administration, key National Institutes of Health committees that approve research grants resumed meeting this week. It appears to be a positive step toward restoring the flow of billions of dollars…
-
STAT+: Trump’s new drug policy mixes ‘harshest’ penalties for dealers and test strips for users
STAT+: Trump’s new drug policy mixes ‘harshest’ penalties for dealers and test strips for users The Trump administration vows to emphasize addiction treatment alongside an enforcement-first drug policy, according to a not-yet-public strategy document obtained by STAT. In an effort to reduce overdose deaths caused by fentanyl and other illicit substances, the administration plans to…
-
STAT+: Makary’s first speech to FDA staff focuses on challenging norms, fighting chronic disease
STAT+: Makary’s first speech to FDA staff focuses on challenging norms, fighting chronic disease WASHINGTON — Marty Makary’s first address to staff as FDA commissioner on Wednesday afternoon sounded a bit like an introduction to one of his books. It included sweeping declarations about the need to challenge scientific norms, and to identify the root…
-
STAT+: FDA Commissioner Marty Makary gets off to a bruising start as agency is wracked by layoffs
STAT+: FDA Commissioner Marty Makary gets off to a bruising start as agency is wracked by layoffs WASHINGTON — Marty Makary’s first official day as commissioner of the Food and Drug Administration began with employees in tears, learning from security guards that they were losing their jobs. The news release announcing the start of his…
-
STAT+: HHS emergency response unit given two days to figure out its fate
STAT+: HHS emergency response unit given two days to figure out its fate WASHINGTON — Robert F. Kennedy Jr.’s plan to reshape the federal health department has left its roughly 1,000 emergency response workers in limbo, and with a daunting order: Sort out how you break up — this weekend. The George W. Bush-founded Administration for…